Case Control Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Nov 14, 2019; 25(42): 6322-6341
Published online Nov 14, 2019. doi: 10.3748/wjg.v25.i42.6322
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Length distribution analysis of sequencing data.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 A receiver operating characteristic curve analysis for candidate microRNAs in hepatocellular carcinoma vs liver cirrhosis groups. AUC: Area under the curve; miRNA: MicroRNA.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 A receiver operating characteristic curve analysis for candidate microRNAs in hepatocellular carcinoma vs nonmalignant groups. AUC: Area under the curve; miRNA: MicroRNA.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 A receiver operating characteristic curve analysis for combined panel. A: A receiver operating characteristic (ROC) curve analysis for combined panel for discriminating hepatocellular carcinoma (HCC) out of liver cirrhosis. B: A ROC curve analysis for combined panel for discriminating HCC out of nonmalignant groups. HCC: Hepatocellular carcinoma; LC: Liver cirrhosis.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 A receiver operating characteristic curve analysis for candidate microRNAs against alpha-fetoprotein. A: Diabetic-associated hepatocellular carcinoma (HCC) vs diabetic nonmalignant patients. B: Diabetic-associated HCC vs diabetic-associated liver cirrhosis. AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma; miRNA: MicroRNA.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 MicroRNAs in correlation to ligand independent c-Met activation and progression of hepatocellular carcinoma in type 2 diabetes mellitus patients. HCC: Hepatocellular carcinoma; miRNA: MicroRNA; NAFLD: Nonalcoholic fatty liver disease; T2DM: Type 2 diabetes mellitus.